Lucid Diligence Brief: Poplar Therapeutics $95 million Series A
Lucid Diligence Brief: Poplar Therapeutics $95 million Series A extension…
Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and Tedopi
Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and…
Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC
Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC Professional…
Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration
Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration Professional…
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics…
Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology
Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology…
Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on genetic epilepsies
Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on…
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel) Professional…
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir in COPD
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir…
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal…
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL Professional audiences…
Lucid Diligence Brief: Ubie and Mayo Clinic's digital front door partnership
Lucid Diligence Brief: Ubie and Mayo Clinic's digital front door partnership…